Cancer chemoprevention: scientific promise, clinical uncertainty (Q34456971)

2 August 2017

1 reference

title

Cancer chemoprevention: scientific promise, clinical uncertainty (English)

1 reference

2 August 2017

Michael B Sporn

1

1 reference

PubMed ID

16205771

2 August 2017

Karen T Liby

series ordinal

2

1 reference

2 August 2017

1 October 2005

1 reference

Nature Clinical Practice Oncology

2 August 2017

1 reference

2 August 2017

2

1 reference

2 August 2017

518-525

1 reference

2 August 2017

10

1 reference

https://scigraph.springernature.com/pub.10.1038/ncponc0319

2 August 2017

0 references

cites work

Chemoprevention: an essential approach to controlling cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

Radical causes of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

Oxyradicals and DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

21 January 2018

Inflammation and cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

Smoldering and polarized inflammation in the initiation and promotion of malignant disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

Mechanisms of disease: Inflammatory mediators and cancer prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

The history of cancer epigenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

The electrophile counterattack response: protection against neoplasia and toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

Chemoprevention through the Keap1-Nrf2 signaling pathway by phase 2 enzyme inducers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

Nrf2 as a novel molecular target for chemoprevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

Regulatory mechanisms controlling gene expression mediated by the antioxidant response element

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

Control of nitric oxide production by transforming growth factor-beta1: mechanistic insights and potential relevance to human disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

TGF-beta1 stimulates HO-1 via the p38 mitogen-activated protein kinase in A549 pulmonary epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

Statins and the risk of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

Inflammation, atherosclerosis, and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

Rosuvastatin upregulates the antioxidant defense protein heme oxygenase-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

Simvastatin induces heme oxygenase-1: a novel mechanism of vessel protection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

Simvastatin attenuates expression of cytokine-inducible nitric-oxide synthase in embryonic cardiac myoblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

Gemcitabine combined with paclitaxel or paclitaxel/trastuzumab in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

Targeting the PI3K-Akt pathway in human cancer: rationale and promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

21 January 2018

Putting the rap on Akt.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

Transcription factors as targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

NF-kappaB functions as a tumour promoter in inflammation-associated cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

Roles and regulation of stat family transcription factors in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

The STATs of cancer--new molecular targets come of age

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

A new modality for immunosuppression: targeting the JAK/STAT pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

Retinoid targeting of different D-type cyclins through distinct chemopreventive mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor beta-dependent apoptosis in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

Points of control in inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

Endogenous generation of reactive oxidants and electrophiles and their reactions with DNA and protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

Inflammation in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

Inflammatory processes in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

Modifying specific cysteines of the electrophile-sensing human Keap1 protein is insufficient to disrupt binding to the Nrf2 domain Neh2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

Cancer: what should be done?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

7 January 2021

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

7 January 2021

Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

7 January 2021

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

7 January 2021

Peptide growth factors and inflammation, tissue repair, and cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

7 January 2021

https://api.crossref.org/works/10.1038%2FNCPONC0319

1 reference

7 January 2021

Epigenetics and cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

7 January 2021

Importance of phase 2 gene regulation in protection against electrophile and reactive oxygen toxicity and carcinogenesis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

7 January 2021

The biology and clinical relevance of the PTEN tumor suppressor pathway

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

7 January 2021

Validating Stat3 in cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

7 January 2021

Cyclin D1 as a target for chemoprevention

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

7 January 2021

Mitochondria, Oxidative Damage, and Inflammation in Parkinson's Disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

7 January 2021

Nrf2 controls constitutive and inducible expression of ARE-driven genes through a dynamic pathway involving nucleocytoplasmic shuttling by Keap1

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0319

7 January 2021

Identifiers

DOI

10.1038/NCPONC0319

1 reference

PubMed ID

16205771

Dimensions Publication ID

2 August 2017

0 references

1 reference

PubMed ID

16205771